SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-22-001919
Filing Date
2022-05-12
Accepted
2022-05-12 08:20:09
Documents
29
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q zk2227748.htm   iXBRL 10-Q 627564
2 EXHIBIT_31-1 exhibit_31-1.htm EX-31.1 14062
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 14281
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 5681
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 5734
  Complete submission text file 0001178913-22-001919.txt   1968080

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmmb-20220331.xsd EX-101.SCH 19593
7 XBRL CALCULATION FILE cmmb-20220331_cal.xml EX-101.CAL 23651
8 XBRL DEFINITION FILE cmmb-20220331_def.xml EX-101.DEF 50680
9 XBRL LABEL FILE cmmb-20220331_lab.xml EX-101.LAB 179412
10 XBRL PRESENTATION FILE cmmb-20220331_pre.xml EX-101.PRE 96676
23 EXTRACTED XBRL INSTANCE DOCUMENT zk2227748_htm.xml XML 117196
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38807 | Film No.: 22915815
SIC: 2834 Pharmaceutical Preparations